Sign in

Private company

BIOLASE, INC

American dental equipment and supplies company based in Lake Forest2

In its 2024 annual report the company says: “We develop, manufacture, market, and sell laser systems that provide significant benefits for dental practitioners and their patients. Our laser systems are designed to provide clinically superior results for many types of dental procedures compared to those achieved with drills, scalpels, and other conventional instruments. We offer two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems.”5

Last updated Oct 21, 2026.

Overview

  • IndustryDental Equipment & Supplies2
  • HeadquartersWilmington, United States2
  • Incorporated inDE3
  • Business address27042 Towne Centre Drive, Suite 270, Foothill Ranch, Ca 926103
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300XJRS7X5LH3QM402
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 21172792

See how the biggest companies compare on our leaderboards

BIOLASE, Inc. (“BIOLASE” and, together with its consolidated subsidiaries, the “Company,” “we,” “our” or “us”) is a leading provider of advanced laser systems for the dental industry. We develop, manufacture, market, and sell laser systems that provide significant benefits for dental practitioners and their patients. Our proprietary systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. Our laser systems are designed to provide clinically superior results for many types of dental procedures compared to those achieved with drills, scalpels, and other conventional instruments. Potential patient benefits include less pain, fewer shots, faster healing, decreased fear and anxiety, and fewer appointme…5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

34.0%Gross margin6
-36.5%Operating margin6
-42.0%Net margin6
1.4%Revenue growth, 20236
-$15.4MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue66¢$32.4M
  • Research and development12¢$6.0M
  • Other costs22¢$10.7M
  • Income tax0¢$31.0K

Out of $49.2M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$49.2M in 2023+5% since 2017
0$20.0M$40.0M$60.0M2017: $46.9M$46.9M20172018: $46.2M$46.2M2018−2%2019: $37.8M$37.8M2019−18%2020: $22.8M$22.8M2020−40%2021: $39.2M$39.2M2021+72%2022: $48.5M$48.5M2022+24%2023: $49.2M$49.2M2023+1%
Gross profit789106$16.7M in 2023+11% since 2017
0$5.0M$10.0M$15.0M$20.0M2017: $15.1M$15.1M20172018: $16.9M$16.9M2018+12%2019: $14.3M$14.3M2019−15%2020: $6.2M$6.2M2020−57%2021: $16.5M$16.5M2021+168%2022: $15.9M$15.9M2022−4%2023: $16.7M$16.7M2023+5%
Operating income789106-$17.9M in 2023−1% since 2017
-$30.0M-$20.0M-$10.0M02017: -$18.0M-$18.0M20172018: -$20.9M-$20.9M2018+16%2019: -$15.6M-$15.6M2019−25%2020: -$18.5M-$18.5M2020+19%2021: -$16.4M-$16.4M2021−11%2022: -$25.3M-$25.3M2022+54%2023: -$17.9M-$17.9M2023−29%
Net income789106-$20.6M in 2023+22% since 2017
-$30.0M-$20.0M-$10.0M02017: -$16.9M-$16.9M20172018: -$21.5M-$21.5M2018+28%2019: -$17.9M-$17.9M2019−17%2020: -$16.8M-$16.8M2020−6%2021: -$16.2M-$16.2M2021−4%2022: -$28.6M-$28.6M2022+77%2023: -$20.6M-$20.6M2023−28%
Fiscal year2017201820192020202120222023
Revenue$46.9M7$46.2M8$37.8M9$22.8M10$39.2M6$48.5M6$49.2M6
Cost of revenue$31.8M7$29.3M8$23.5M9$16.6M10$22.7M6$32.6M6$32.4M6
Gross profit$15.1M7$16.9M8$14.3M9$6.2M10$16.5M6$15.9M6$16.7M6
Research and development$6.2M7$5.2M8$4.8M9$3.7M10$6.0M6$7.3M6$6.0M6
Operating expenses$33.0M6$41.2M6$34.7M6
Operating income-$18.0M7-$20.9M8-$15.6M9-$18.5M10-$16.4M6-$25.3M6-$17.9M6
Income before tax-$16.1M6-$28.5M6-$20.6M6
Income tax-$582.0K7$63.0K8-$44.0K9$128.0K10$65.0K6$109.0K6$31.0K6
Net income-$16.9M7-$21.5M8-$17.9M9-$16.8M10-$16.2M6-$28.6M6-$20.6M6
Earnings per share-$1.417-$1.058-$0.778-$13.9910-$283.126-$418.136-$29.446
Earnings per share (diluted)-$1.417-$1.058-$0.778-$13.9910-$283.126-$418.136-$29.446
Shares (weighted, basic)59.0K shares669.0K shares61.3M shares6
Shares (weighted, diluted)59.0K shares669.0K shares61.3M shares6

Compare BIOLASE, INC with another company

Corporate structure

BIOLASE, INC sits at the top of its group. 8 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BIOLASE, INC

  • BIOLASE, INC Wilmington, Delaware, United States
    • Biolase Australia, Pty. Ltd. Subsidiary · Australia
    • Biolase Europe, GmbH Subsidiary · Germany
    • Biolase India Private Limited Subsidiary · India
    • Biolase Spain, S.L. Subsidiary · Spain
    • BL Acquisition Corp. Subsidiary · Delaware, United States
    • BL Acquisition II, Inc. Subsidiary · Delaware, United States
    • Model Dental Office, LLC Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BIOLASE, INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Land$160.0K6 Dec 31, 2023$155.0K6 Dec 31, 2022+3.2%
Accumulated depreciation$11.3M6 Dec 31, 2023$8.5M6 Dec 31, 2022+32.7%
Property and equipment, net$5.5M6 Dec 31, 2023$4.3M6 Dec 31, 2022+29.1%
Operating-lease assets (leased space)$1.5M6 Dec 31, 2023$1.8M6 Dec 31, 2022−14.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.6M6 Dec 31, 2023$4.2M6 Dec 31, 2022+57.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$2.9M6 Dec 31, 2023$2.9M6 Dec 31, 20220%
Finite-lived intangibles, gross$2.8M6 Dec 31, 2023$2.8M6 Dec 31, 20220%
Accumulated amortization$2.8M6 Dec 31, 2023$2.8M6 Dec 31, 20220%

Inventory

ItemLatestA year beforeChange
Inventory, total$11.4M6 Dec 31, 2023$15.9M6 Dec 31, 2022−28.0%
Raw materials$6.2M6 Dec 31, 2023$6.7M6 Dec 31, 2022−7.9%
Work in process$1.3M6 Dec 31, 2023$1.9M6 Dec 31, 2022−30.6%
Finished goods$4.0M6 Dec 31, 2023$7.3M6 Dec 31, 2022−45.8%

Leadership

Who has led BIOLASE, INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Federico Pignatelli2008–2012
  2. Philip Jake St2008
  3. David M. Mulder2009
  4. Jeffrey M. Nugent2014
  5. Harold C. Flynn Jr.2015–2017
  6. Todd Norbe2018–2020
  7. John R. Beaver2021–2023

Chair

  1. Federico Pignatelli2011–2012

President

  1. Federico Pignatelli2009
  2. Alexander K. Arrow2013–2014
  3. Harold C. Flynn Jr.2015–2017
  4. Todd Norbe2018–2020
  5. John R. Beaver2021–2023

Chief financial officer

  1. Richard L. Harrison2007
  2. Fred Capallo2008–2009
  3. David M. Mulder2008–2009
  4. Brett L. Scott2009
  5. Frederick D. Furry2010–2014
  6. David C. Dreyer2015–2016
  7. Mark Joseph Nelson2017
  8. John R. Beaver2017–2020
  9. Jennifer Bright2022–2023

Chief operating officer

  1. Alexander K. Arrow2013–2014
  2. Steven Sandor2022–2023
2010201520202025
Board members and other officers (32)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • BL Acquisition Corp. Delaware4
  • BL Acquisition II, Inc. Delaware4
  • Biolase Australia, Pty. Ltd. AUSTRALIA4
  • Biolase Europe, GmbH GERMANY4
  • Biolase India Private Limited INDIA4
  • Biolase Spain, S.L. SPAIN4
  • Model Dental Office, LLC Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • BIOLASE TECHNOLOGY INCNov 15, 1996 to May 30, 20123

Timeline

  1. Oct 8, 20248-K Listing notice or transfer62
  2. Oct 1, 20248-K Entered a material agreement; Bankruptcy or receivership; Debt or obligation accelerated63
  3. Sep 6, 20248-K Entered a material agreement; Listing notice or transfer64
  4. Aug 28, 20248-K Debt or obligation accelerated65
  5. Aug 8, 20248-K Results of operations66
  6. Jul 22, 20248-K Unregistered sale of shares67
  7. Jun 18, 20248-K Listing notice or transfer68
  8. May 17, 20248-K Listing notice or transfer69
  9. May 13, 20248-K Results of operations70
  10. May 6, 20248-K Shareholder vote71
  11. Apr 19, 20248-K Listing notice or transfer72
  12. Mar 21, 20248-K Results of operations73
  13. Mar 26, 2021New chief executive John R. Beaver becomes CEO15
  14. Sep 25, 2018New chief executive Todd Norbe becomes CEO16
  15. Jul 20, 2015New chief executive Harold C. Flynn Jr. becomes CEO17
  16. Jul 23, 2014New chief executive Jeffrey M. Nugent becomes CEO18
  17. Mar 11, 2009New chief executive David M. Mulder becomes CEO19
  18. Jan 11, 2008New chief executive Philip Jake St becomes CEO21
  19. Jan 2, 2008New chief executive Federico Pignatelli becomes CEO20

Calendar

When it reported results

  1. Aug 8, 2024Reported quarterly or annual results66
  2. May 13, 2024Reported quarterly or annual results70
  3. Mar 21, 2024Reported quarterly or annual results73
  4. Feb 7, 2024Reported quarterly or annual results74
  5. Jan 29, 2024Reported quarterly or annual results75
  6. Nov 9, 2023Reported quarterly or annual results76
  7. Aug 10, 2023Reported quarterly or annual results77
  8. May 11, 2023Reported quarterly or annual results78

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

214 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 53 major events, 33 insider forms, 15 large holders, 1 private raises, 99 other. The latest 20:

  1. Apr 21, 2025SEC STAFF ACTION EDGAR
  2. Nov 14, 2024SC 13G/A EDGAR
  3. Nov 14, 2024SC 13G/A EDGAR
  4. Nov 7, 202410-Q EDGAR
  5. Oct 8, 20248-K EDGAR
  6. Oct 1, 20248-K EDGAR
  7. Sep 6, 202425-NSE EDGAR
  8. Sep 6, 20248-K EDGAR
  9. Aug 28, 20248-K EDGAR
  10. Aug 8, 202410-Q EDGAR
  11. Aug 8, 20248-K EDGAR
  12. Jul 22, 20248-K EDGAR
  13. Jun 18, 20248-K EDGAR
  14. Jun 3, 2024S-1 REGISTRATION STATEMENT EDGAR
  15. May 17, 20248-K EDGAR
  16. May 13, 202410-Q EDGAR
  17. May 13, 20248-K EDGAR
  18. May 6, 20248-K EDGAR
  19. Apr 23, 2024424B4 EDGAR
  20. Apr 22, 2024EFFECT EDGAR

The 214 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 1 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 7, 2022LORD JONATHAN T MDDirectorSale3,537$0.75$2.7KForm 4
Dec 15, 2021LORD JONATHAN T MDDirectorSale11,038$0.38$4.2KForm 4
Nov 30, 2021BEAVER JOHN RPresident & CEOBuy70,000$0.45$31.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 6, 2023Raised $2.7 million in a private offering of equity Form D: 1 investor so far Form D

SEC filer profile

How BIOLASE, INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBIOLASE, INC1
  • CIK0000811240
  • Employer ID (EIN)87-04424411
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3843 Dental Equipment & Supplies1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address27042 Towne Centre Drive, Suite 270, Foothill Ranch, CA 926101
  • Phone949-361-12001
  • Shares outstanding36,597,334 as of Oct 31, 202413
  • Public float$7.2M as of Jun 30, 20236
  • On EDGAR sinceJul 29, 19961
  • Filings1,418 in all: 8-K (383), 4 (354), 10-Q (84), SC 13D/A (48), 3 (46), CORRESP (38), SC 13G (33), DEF 14A (32)1
    All 55 form types

    SC 13G/A (31), DEFA14A (29), 10-K (26), UPLOAD (26), S-1/A (24), EFFECT (23), S-3/A (21), 8-K/A (20), S-3 (17), 10-Q/A (15), PRE 14A (13), NT 10-Q (12), S-1 (12), 424B3 (11), S-8 (10), 4/A (9), 424B5 (7), CT ORDER (7), SD (7), 10-K/A (6), 424B1 (6), ARS (6), SC 13D (6), 424B4 (5), DFAN14A (5), POS AM (5), D (4), DEFR14A (4), NT 10-K (4), 8-A12G (3), RW (3), 10QSB (2), 3/A (2), 8-A12B/A (2), DEFC14A (2), PREC14A (2), PRER14A (2), S-1MEF (2), 10-K405 (1), 10KSB (1), 25-NSE (1), 8-A12B (1), FWP (1), NTN 10Q (1), POS EX (1), REGDEX (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Mar 21, 2024
    Quarterly report (10-Q) Nov 7, 2024
    Proxy statement (DEF 14A) Mar 22, 2024
    Latest 8-K (8-K) Oct 8, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86